¼¼°èÀÇ Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀå : »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2025-2035³â)
Platelet-rich Plasma Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035
»óǰÄÚµå
:
1788507
¸®¼Ä¡»ç
:
Transparency Market Research
¹ßÇàÀÏ
:
2025³â 06¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 224 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀå - ¿¬±¸ ¹üÀ§
TMRÀÇ Á¶»ç º¸°í¼ "¼¼°èÀÇ Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀå"Àº 2025-2035³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ÁöÇ¥¿¡ ´ëÇÑ ±ÍÁßÇÑ ÅëÂû·ÂÀ» ¾ò±â À§ÇØ °ú°Å¿Í ÇöÀçÀÇ ¼ºÀå µ¿Çâ°ú ±âȸ¸¦ Á¶»çÇß½À´Ï´Ù. ÀÌ º¸°í¼´Â 2025³âÀ» ±âÁØ ¿¬µµ, 2035³âÀ» ¿¹Ãø ¿¬µµ·Î ÇÏ¿© 2025³âºÎÅÍ 2035³â±îÁö Àü ¼¼°è Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀåÀÇ ¸ÅÃâ°ú ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, 2025-2035³â±îÁöÀÇ ¼¼°è Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀåÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)µµ Á¦½ÃÇÕ´Ï´Ù.
º» º¸°í¼´Â ±¤¹üÀ§ÇÑ Á¶»ç¸¦ ÅëÇØ ÀÛ¼ºµÇ¾ú½À´Ï´Ù. 1Â÷ Á¶»ç¿¡¼ ¾Ö³Î¸®½ºÆ®´Â KOL(Key Opinion Leader), ¾÷°è ¸®´õ, ¿ÀÇǴϾð Á¦Á¶¾÷ü¸¦ ´ë»óÀ¸·Î ÀÎÅͺ並 ÁøÇàÇß½À´Ï´Ù. 2Â÷ Á¶»ç¿¡¼´Â ÁÖ¿ä ±â¾÷ÀÇ Á¦Ç° ÀÚ·á, ¿¬·Ê º¸°í¼, º¸µµÀÚ·á, °ü·Ã ¹®¼ µîÀ» ÂüÁ¶ÇÏ¿© Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀåÀ» Ãß·ÐÇß½À´Ï´Ù.
½ÃÀå ÇöȲ
½ÃÀå ±Ô¸ð(2024³â)
8,476¾ï ´Þ·¯
½ÃÀå ±Ô¸ð(2035³â)
23¾ï ´Þ·¯
CAGR
9.6%
ÀÌ º¸°í¼´Â ¼¼°è Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀå °æÀï ±¸µµ¸¦ Á¶»çÇß½À´Ï´Ù. ¼¼°è Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀå¿¡¼ »ç¾÷À» ¿î¿µÇÏ´Â ÁÖ¿ä ±â¾÷ÀÌ È®ÀεǾúÀ¸¸ç, °¢ ±â¾÷Àº ´Ù¾çÇÑ ¼Ó¼ºº°·Î ÇÁ·ÎÆÄÀϸµµÇ¾ú½À´Ï´Ù. ±â¾÷ °³¿ä, À繫 »óÅÂ, ÃÖ±Ù °³¹ß, SWOT´Â ÀÌ º¸°í¼¿¡ Æ÷ÇÔµÈ ¼¼°è Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀå ±â¾÷ÀÇ ¼Ó¼ºÀÔ´Ï´Ù.
¼¼°è Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀå º¸°í¼°¡ ´äº¯ÇÑ ÁÖ¿ä Áú¹®Àº ´ÙÀ½°ú °°½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ¸ðµç Áö¿ªÀÇ ¾ÆÆç·¹½Ã½º ¸ÅÃâ/¼öÀÍÀº?
¼¼°è Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀå¿¡¼ÀÇ ºñÁî´Ï½º ±âȸ´Â?
½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎ, ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ, ±âȸ, À§Çù ¿äÀÎÀº ¹«¾ùÀΰ¡?
¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ Áö¿ª ½ÃÀåÀº ¾îµðÀΰ¡?
2035³â ¼¼°è¿¡¼ °¡Àå ³ôÀº ¼öÀÍÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ºÐ¾ß´Â?
¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ºÎ¹®Àº?
¼¼°è ½ÃÀå¿¡¼ »ç¾÷À» Àü°³ÇÏ´Â °¢ ±â¾÷ ½ÃÀå ÁöÀ§´Â?
Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀå - Á¶»ç ¸ñÀû ¹× Á¶»ç ¹æ¹ý
¼¼°è Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ º¸°í¼´Â °³¿ä·Î ½ÃÀÛÇÏ¿© ¿¬±¸ ¹üÀ§¿Í ¸ñÀûÀÌ À̾îÁý´Ï´Ù. º» Á¶»çÀÇ ¸ñÀû, ½ÃÀå¿¡¼ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä º¥´õ¿Í À¯Åë¾÷ü, Á¦Ç° ½ÂÀο¡ °üÇÑ ±ÔÁ¦ ½Ã³ª¸®¿À¿¡ ´ëÇØ »ó¼¼ÇÏ°Ô ¼³¸íÇÕ´Ï´Ù.
º» º¸°í¼´Â °¡µ¶¼ºÀ» °í·ÁÇÏ¿© °¢ ¼½¼ÇÀ» À庰·Î ³ª´©¾î ·¹À̾ƿôÀ» ±¸¼ºÇÏ¿´½À´Ï´Ù. º» º¸°í¼´Â ±×·¡ÇÁ¿Í Ç¥¸¦ ÀûÀýÈ÷ ¹èÄ¡ÇÑ Á¾ÇÕÀûÀÎ ÀÚ·á·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ÁÖ¿ä ºÎ¹®ÀÇ ºÐ¼®°ú ¿¹ÃøÄ¡¸¦ µµ½ÄÈÇÏ¿© µ¶ÀÚ¿¡°Ô ½Ã°¢ÀûÀ¸·Î ¾îÇÊÇÕ´Ï´Ù. ¶ÇÇÑ, °ú°Å¿Í ¿¹Ãø ±â°£ ¸»ÀÇ ÁÖ¿ä ºÎ¹®º° ½ÃÀå Á¡À¯À²À» ºñ±³ÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼´Â ¼¼°è Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀåÀ» À¯Çü, °ø±Þ¿ø, Áö¿ªº°·Î ºÐ¼®ÇÕ´Ï´Ù. °¢ ±âÁØÀÇ ÁÖ¿ä ºÎ¹®À» »ó¼¼ÇÏ°Ô Á¶»çÇϰí, 2035³â ¸» ±âÁØ °¢ ºÎ¹® ½ÃÀå Á¡À¯À²À» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±ÍÁßÇÑ ÅëÂû·ÂÀ» ÅëÇØ ½ÃÀå ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀå¿¡ ´ëÇÑ ÅõÀÚ¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ºñÁî´Ï½º ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå ÀüÁ¦Á¶°Ç°ú Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à : ¼¼°è ½ÃÀå
Á¦4Àå ½ÃÀå °³¿ä
¼·Ð
°³¿ä
½ÃÀå ¿ªÇÐ
¼¼°èÀÇ Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ½ÃÀå ºÐ¼®°ú ¿¹Ãø(2020-2035³â)
Á¦5Àå ÁÖ¿ä ÀλçÀÌÆ®
ÁÖ¿ä Áö¿ª/±¹°¡ ÀÇ·áºñ ÁöÃâ
Ç÷¼ÒÆÇ dzºÎ Ç÷Àå Ä¡·á ±â¼ú Áøº¸
ÁÖ¿ä Áö¿ª/±¹°¡ ±ÔÁ¦ ½Ã³ª¸®¿À
PorterÀÇ Five Forces ºÐ¼®
PESTEL ºÐ¼®
¹ë·ùüÀÎ ºÐ¼®
ÃÖÁ¾»ç¿ëÀÚ¿¡ ÀÖ¾î¼ÀÇ ÁÖ¿ä ±¸ÀÔ ÁöÇ¥
½Å±Ô ½ÃÀå Âü¿© »ç¶÷À» À§ÇÑ ½ÃÀå °³Ã´ Àü·«
ÁÖ¿ä ¾÷°è À̺¥Æ®(ÆÄÆ®³Ê½Ê, Çù¾÷, Á¦Ç° ½ÂÀÎ, ÇÕº´ ¹× Àμö)
ÁÖ¿ä °æÀïÀÌ Á¦°øÇÏ´Â ÁÖ¿ä Á¦Ç° º¥Ä¡¸¶Å·
Á¦6Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : À¯Çüº°(PRP)
¼·Ð ¹× Á¤ÀÇ
ÁÖ¿ä ºÐ¼® °á°ú/ÁøÀü
½ÃÀå ¿¹Ãø(±Ý¾× ±âÁØ) : À¯Çüº°(PRP)(2020-2035³â)
Pure Platelet-Rich Plasma (P-PRP)
Leukocyte-and Platelet-Rich Plasma (L-PRP)
Pure Platelet-Rich Fibrin (P-PRF)
Leukocyte- and Platelet-Rich Fibrin (L-PRF)
½ÃÀåÀÇ ¸Å·Â : À¯Çüº°(PRP)
Á¦7Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : °ø±Þ¿øº°
¼·Ð ¹× Á¤ÀÇ
ÁÖ¿ä ºÐ¼® °á°ú/ÁøÀü
½ÃÀå ¿¹Ãø(±Ý¾× ±âÁØ) : °ø±Þ¿øº°(2020-2035³â)
½ÃÀåÀÇ ¸Å·Â : °ø±Þ¿øº°
Á¦8Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ¿ëµµº°
¼·Ð ¹× Á¤ÀÇ
ÁÖ¿ä ºÐ¼® °á°ú/ÁøÀü
½ÃÀå ¿¹Ãø(±Ý¾× ±âÁØ) : ¿ëµµº°(2020-2035³â)
Á¤Çü¿Ü°ú
°üÀý¿°
¸¸¼º°Ç¿°
»À ¼öº¹ ¹× Àç»ý
½ºÆ÷Ã÷ ÀÇÇÐ
ÇǺΰú ¹× â»ó Ä¡À¯
±Ë¾ç Ä¡·á
Á¤¸Æ ±Ë¾ç
¿Ü»ó¼º ±Ë¾ç
´ç´¢º´¼º ±Ë¾ç
Ç÷°ü¿°¼º ±Ë¾ç
±âŸ
ÆäÀÌ¼È È¸Ãá
À°¸ð
±âŸ
¹Ì¿ë¼ºÇü
¾È°ú ¼ö¼ú
³ú½Å°æ¿Ü°ú
½ÉÀå ¼ö¼ú
ÀϹݿܰú
±âŸ
½ÃÀåÀÇ ¸Å·Â : ¿ëµµº°
Á¦9Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°
¼·Ð ¹× Á¤ÀÇ
ÁÖ¿ä ºÐ¼® °á°ú/ÁøÀü
½ÃÀå ¿¹Ãø(±Ý¾× ±âÁØ) : ÃÖÁ¾»ç¿ëÀÚº°(2020-2035³â)
º´¿ø ¹× ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
ÇǺΰú ¹× ¹Ì¿ë Ŭ¸®´Ð
Ä¡°úÀÇ¿ø
½ºÆ÷Ã÷ Ŭ¸®´Ð ¹× ÀçȰġ·á¼¾ÅÍ
±âŸ
½ÃÀåÀÇ ¸Å·Â : ÃÖÁ¾»ç¿ëÀÚº°
Á¦10Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°
ÁÖ¿ä ºÐ¼® °á°ú
½ÃÀå ¿¹Ãø(±Ý¾× ±âÁØ) : : Áö¿ªº°
ºÏ¹Ì
À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
½ÃÀåÀÇ ¸Å·Â : Áö¿ªº°
Á¦11Àå ºÏ¹Ì ½ÃÀå ºÐ¼®°ú ¿¹Ãø
Á¦12Àå À¯·´ ½ÃÀå ºÐ¼®°ú ¿¹Ãø
µ¶ÀÏ
¿µ±¹
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
½ºÀ§½º
³×´ú¶õµå
±âŸ À¯·´
Á¦13Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ºÐ¼®°ú ¿¹Ãø
Áß±¹
Àεµ
ÀϺ»
Çѱ¹
È£ÁÖ ¹× ´ºÁú·£µå
±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
Á¦14Àå ¶óÆ¾¾Æ¸Þ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø
ºê¶óÁú
¸ß½ÃÄÚ
¾Æ¸£ÇîÆ¼³ª
±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
Á¦15Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø
GCC ±¹°¡
³²¾ÆÇÁ¸®Ä«°øÈ±¹
±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦16Àå °æÀï ±¸µµ
½ÃÀå ±â¾÷ - °æÀï ¸ÅÆ®¸¯½º(±â¾÷ Tierº°, ±Ô¸ðº°)
½ÃÀå Á¡À¯À² ºÐ¼® ±â¾÷º°(2024³â)
±â¾÷ °³¿ä
Johnson & Johnson Services, Inc.
Stryker
Zimmer Biomet
Arthrex, Inc.
Terumo BCT, Inc.
Crown Aesthetics
Celling Biosciences
EmCyte Corporation
Juventix Regenerative Medical, LLC.
APEX Biologix
Dr PRP USA LLC
Changsha Yingtai Instrument Co., Ltd.
Accuquik Test Kits
Aspire Medical Innovation
Factor Medical, Inc.
LSH
¿µ¹® ¸ñÂ÷
Platelet-rich Plasma Market- Scope of Report
TMR's report on the global Platelet-rich Plasma Marketstudies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global Platelet-rich Plasma Marketfor the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Platelet-rich Plasma Marketfrom 2025 to 2035.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the two-wheeler navigation display market.
Market Snapshot
Market Value in 2024 US$ 847.6 Bn
Market Value in 2035 US$ 2.3 Bn
CAGR 9.6%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global two-wheeler navigation display market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global two-wheeler navigation display market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global two-wheeler navigation display market.
The report delves into the competitive landscape of the global two-wheeler navigation display market. Key players operating in the global Platelet-rich Plasma Markethave been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Platelet-rich Plasma Marketprofiled in this report.
Key Questions Answered in Global Platelet-rich Plasma MarketReport:
What is the sales/revenue generated by apheresis across all regions during the forecast period?
What are the opportunities in the global two-wheeler navigation display market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Platelet-rich Plasma Market- Research Objectives and Research Approach
The comprehensive report on the global Platelet-rich Plasma Marketbegins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Platelet-rich Plasma Marketin terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global two-wheeler navigation display market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Platelet-rich Plasma Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Platelet-rich Plasma Market Analysis and Forecasts, 2020 to 2035
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Healthcare Expenditure across Key Regions / Countries
5.2. Technological Advancements in Platelet-rich Plasma Treatment
5.3. Regulatory Scenario across Key Regions / Countries
5.4. PORTER's Five Forces Analysis
5.5. PESTEL Analysis
5.6. Value Chain Analysis
5.7. Key Purchase Metrics for End-users
5.8. Go-to-Market Strategy for New Market Entrants
5.9. Key Industry Events (Partnerships, Collaborations, Product approvals, mergers & acquisitions)
5.10. Benchmarking of Key Products Offered by the Leading Competitors
6. Global Platelet-rich Plasma Market Analysis and Forecasts, By Type of Platelet-rich Plasma (PRP)
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Type of Platelet-rich Plasma (PRP), 2020 to 2035
6.3.1. Pure Platelet-Rich Plasma (P-PRP)
6.3.2. Leukocyte-and Platelet-Rich Plasma (L-PRP)
6.3.3. Pure Platelet-Rich Fibrin (P-PRF)
6.3.4. Leukocyte- and Platelet-Rich Fibrin (L-PRF)
6.4. Market Attractiveness By Type of Platelet-rich Plasma (PRP)
7. Global Platelet-rich Plasma Market Analysis and Forecasts, By Source
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Source, 2020 to 2035
7.3.1. Autologous PRP
7.3.2. Allogenic PRP
7.4. Market Attractiveness By Source
8. Global Platelet-rich Plasma Market Analysis and Forecasts, By Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Application, 2020 to 2035
8.3.1. Orthopedics
8.3.1.1. Arthritis
8.3.1.2. Chronic Tendinitis
8.3.1.3. Bone Repair and Regeneration
8.3.2. Sports Medicine
8.3.3. Dermatology / Wound Healing
8.3.3.1. Ulcer Healing
8.3.3.1.1. Venous Ulcer
8.3.3.1.2. Traumatic Ulcer
8.3.3.1.3. Diabetic Ulcer
8.3.3.1.4. Vasculitic Ulcer
8.3.3.1.5. Others
8.3.3.2. Facial Rejuvenation
8.3.3.3. Hair Restoration
8.3.3.4. Others
8.3.4. Cosmetic Surgery
8.3.5. Ophthalmic Surgery
8.3.6. Neurosurgery
8.3.7. Cardiac Surgery
8.3.8. General Surgery
8.3.9. Others
8.4. Market Attractiveness By Application
9. Global Platelet-rich Plasma Market Analysis and Forecasts, By End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By End-user, 2020 to 2035
9.3.1. Hospitals and Ambulatory Surgical Centers
9.3.2. Dermatology and Aesthetic Clinics
9.3.3. Dental Clinics
9.3.4. Sport Clinics and Rehabilitation Centers
9.3.5. Others
9.4. Market Attractiveness By End-user
10. Global Platelet-rich Plasma Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Region
11. North America Platelet-rich Plasma Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast By Type of Platelet-rich Plasma (PRP), 2020 to 2035
11.2.1. Pure Platelet-Rich Plasma (P-PRP)
11.2.2. Leukocyte-and Platelet-Rich Plasma (L-PRP)
11.2.3. Pure Platelet-Rich Fibrin (P-PRF)
11.2.4. Leukocyte- and Platelet-Rich Fibrin (L-PRF)
11.3. Market Value Forecast By Source, 2020 to 2035
11.3.1. Autologous PRP
11.3.2. Allogenic PRP
11.4. Market Value Forecast By Application, 2020 to 2035
11.4.1. Orthopedics
11.4.1.1. Arthritis
11.4.1.2. Chronic Tendinitis
11.4.1.3. Bone Repair and Regeneration
11.4.2. Sports Medicine
11.4.3. Dermatology / Wound Healing
11.4.3.1. Ulcer Healing
11.4.3.1.1. Venous Ulcer
11.4.3.1.2. Traumatic Ulcer
11.4.3.1.3. Diabetic Ulcer
11.4.3.1.4. Vasculitic Ulcer
11.4.3.1.5. Others
11.4.3.2. Facial Rejuvenation
11.4.3.3. Hair Restoration
11.4.3.4. Others
11.4.4. Cosmetic Surgery
11.4.5. Ophthalmic Surgery
11.4.6. Neurosurgery
11.4.7. Cardiac Surgery
11.4.8. General Surgery
11.4.9. Others
11.5. Market Value Forecast By End-user, 2020 to 2035
11.5.1. Hospitals and Ambulatory Surgical Centers
11.5.2. Dermatology and Aesthetic Clinics
11.5.3. Dental Clinics
11.5.4. Sport Clinics and Rehabilitation Centers
11.5.5. Others
11.6. Market Value Forecast By Country, 2020 to 2035
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Type of Platelet-rich Plasma (PRP)
11.7.2. By Source
11.7.3. By Application
11.7.4. By End-user
11.7.5. By Country
12. Europe Platelet-rich Plasma Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast By Type of Platelet-rich Plasma (PRP), 2020 to 2035
12.2.1. Pure Platelet-Rich Plasma (P-PRP)
12.2.2. Leukocyte-and Platelet-Rich Plasma (L-PRP)
12.2.3. Pure Platelet-Rich Fibrin (P-PRF)
12.2.4. Leukocyte- and Platelet-Rich Fibrin (L-PRF)
12.3. Market Value Forecast By Source, 2020 to 2035
12.3.1. Autologous PRP
12.3.2. Allogenic PRP
12.4. Market Value Forecast By Application, 2020 to 2035
12.4.1. Orthopedics
12.4.1.1. Arthritis
12.4.1.2. Chronic Tendinitis
12.4.1.3. Bone Repair and Regeneration
12.4.2. Sports Medicine
12.4.3. Dermatology / Wound Healing
12.4.3.1. Ulcer Healing
12.4.3.1.1. Venous Ulcer
12.4.3.1.2. Traumatic Ulcer
12.4.3.1.3. Diabetic Ulcer
12.4.3.1.4. Vasculitic Ulcer
12.4.3.1.5. Others
12.4.3.2. Facial Rejuvenation
12.4.3.3. Hair Restoration
12.4.3.4. Others
12.4.4. Cosmetic Surgery
12.4.5. Ophthalmic Surgery
12.4.6. Neurosurgery
12.4.7. Cardiac Surgery
12.4.8. General Surgery
12.4.9. Others
12.5. Market Value Forecast By End-user, 2020 to 2035
12.5.1. Hospitals and Ambulatory Surgical Centers
12.5.2. Dermatology and Aesthetic Clinics
12.5.3. Dental Clinics
12.5.4. Sport Clinics and Rehabilitation Centers
12.5.5. Others
12.6. Market Value Forecast By Country / Sub-region, 2020 to 2035
12.6.1. Germany
12.6.2. UK
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Switzerland
12.6.7. The Netherlands
12.6.8. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Type of Platelet-rich Plasma (PRP)
12.7.2. By Source
12.7.3. By Application
12.7.4. By End-user
12.7.5. By Country / Sub-region
13. Asia Pacific Platelet-rich Plasma Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast By Type of Platelet-rich Plasma (PRP), 2020 to 2035
13.2.1. Pure Platelet-Rich Plasma (P-PRP)
13.2.2. Leukocyte-and Platelet-Rich Plasma (L-PRP)
13.2.3. Pure Platelet-Rich Fibrin (P-PRF)
13.2.4. Leukocyte- and Platelet-Rich Fibrin (L-PRF)
13.3. Market Value Forecast By Source, 2020 to 2035
13.3.1. Autologous PRP
13.3.2. Allogenic PRP
13.4. Market Value Forecast By Application, 2020 to 2035
13.4.1. Orthopedics
13.4.1.1. Arthritis
13.4.1.2. Chronic Tendinitis
13.4.1.3. Bone Repair and Regeneration
13.4.2. Sports Medicine
13.4.3. Dermatology / Wound Healing
13.4.3.1. Ulcer Healing
13.4.3.1.1. Venous Ulcer
13.4.3.1.2. Traumatic Ulcer
13.4.3.1.3. Diabetic Ulcer
13.4.3.1.4. Vasculitic Ulcer
13.4.3.1.5. Others
13.4.3.2. Facial Rejuvenation
13.4.3.3. Hair Restoration
13.4.3.4. Others
13.4.4. Cosmetic Surgery
13.4.5. Ophthalmic Surgery
13.4.6. Neurosurgery
13.4.7. Cardiac Surgery
13.4.8. General Surgery
13.4.9. Others
13.5. Market Value Forecast By End-user, 2020 to 2035
13.5.1. Hospitals and Ambulatory Surgical Centers
13.5.2. Dermatology and Aesthetic Clinics
13.5.3. Dental Clinics
13.5.4. Sport Clinics and Rehabilitation Centers
13.5.5. Others
13.6. Market Value Forecast By Country / Sub-region, 2020 to 2035
13.6.1. China
13.6.2. India
13.6.3. Japan
13.6.4. South Korea
13.6.5. Australia & New Zealand
13.6.6. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Type of Platelet-rich Plasma (PRP)
13.7.2. By Source
13.7.3. By Application
13.7.4. By End-user
13.7.5. By Country / Sub-region
14. Latin America Platelet-rich Plasma Market Analysis and Forecast
14.1. Introduction
14.2. Market Value Forecast By Type of Platelet-rich Plasma (PRP), 2020 to 2035
14.2.1. Pure Platelet-Rich Plasma (P-PRP)
14.2.2. Leukocyte-and Platelet-Rich Plasma (L-PRP)
14.2.3. Pure Platelet-Rich Fibrin (P-PRF)
14.2.4. Leukocyte- and Platelet-Rich Fibrin (L-PRF)
14.3. Market Value Forecast By Source, 2020 to 2035
14.3.1. Autologous PRP
14.3.2. Allogenic PRP
14.4. Market Value Forecast By Application, 2020 to 2035
14.4.1. Orthopedics
14.4.1.1. Arthritis
14.4.1.2. Chronic Tendinitis
14.4.1.3. Bone Repair and Regeneration
14.4.2. Sports Medicine
14.4.3. Dermatology / Wound Healing
14.4.3.1. Ulcer Healing
14.4.3.1.1. Venous Ulcer
14.4.3.1.2. Traumatic Ulcer
14.4.3.1.3. Diabetic Ulcer
14.4.3.1.4. Vasculitic Ulcer
14.4.3.1.5. Others
14.4.3.2. Facial Rejuvenation
14.4.3.3. Hair Restoration
14.4.3.4. Others
14.4.4. Cosmetic Surgery
14.4.5. Ophthalmic Surgery
14.4.6. Neurosurgery
14.4.7. Cardiac Surgery
14.4.8. General Surgery
14.4.9. Others
14.5. Market Value Forecast By End-user, 2020 to 2035
14.5.1. Hospitals and Ambulatory Surgical Centers
14.5.2. Dermatology and Aesthetic Clinics
14.5.3. Dental Clinics
14.5.4. Sport Clinics and Rehabilitation Centers
14.5.5. Others
14.6. Market Value Forecast By Country / Sub-region, 2020 to 2035
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Argentina
14.6.4. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Type of Platelet-rich Plasma (PRP)
14.7.2. By Source
14.7.3. By Application
14.7.4. By End-user
14.7.5. By Country / Sub-region
15. Middle East & Africa Platelet-rich Plasma Market Analysis and Forecast
15.1. Introduction
15.2. Market Value Forecast By Type of Platelet-rich Plasma (PRP), 2020 to 2035
15.2.1. Pure Platelet-Rich Plasma (P-PRP)
15.2.2. Leukocyte-and Platelet-Rich Plasma (L-PRP)
15.2.3. Pure Platelet-Rich Fibrin (P-PRF)
15.2.4. Leukocyte- and Platelet-Rich Fibrin (L-PRF)
15.3. Market Value Forecast By Source, 2020 to 2035
15.3.1. Autologous PRP
15.3.2. Allogenic PRP
15.4. Market Value Forecast By Application, 2020 to 2035
15.4.1. Orthopedics
15.4.1.1. Arthritis
15.4.1.2. Chronic Tendinitis
15.4.1.3. Bone Repair and Regeneration
15.4.2. Sports Medicine
15.4.3. Dermatology / Wound Healing
15.4.3.1. Ulcer Healing
15.4.3.1.1. Venous Ulcer
15.4.3.1.2. Traumatic Ulcer
15.4.3.1.3. Diabetic Ulcer
15.4.3.1.4. Vasculitic Ulcer
15.4.3.1.5. Others
15.4.3.2. Facial Rejuvenation
15.4.3.3. Hair Restoration
15.4.3.4. Others
15.4.4. Cosmetic Surgery
15.4.5. Ophthalmic Surgery
15.4.6. Neurosurgery
15.4.7. Cardiac Surgery
15.4.8. General Surgery
15.4.9. Others
15.5. Market Value Forecast By End-user, 2020 to 2035
15.5.1. Hospitals and Ambulatory Surgical Centers
15.5.2. Dermatology and Aesthetic Clinics
15.5.3. Dental Clinics
15.5.4. Sport Clinics and Rehabilitation Centers
15.5.5. Others
15.6. Market Value Forecast By Country / Sub-region, 2020 to 2035
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Type of Platelet-rich Plasma (PRP)
15.7.2. By Source
15.7.3. By Application
15.7.4. By End-user
15.7.5. By Country / Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2024)
16.3. Company Profiles
16.3.1. Johnson & Johnson Services, Inc.
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategies
16.3.1.5. Recent Developments
16.3.2. Stryker
16.3.2.1. Company Overview
16.3.2.2. Financial Overview
16.3.2.3. Product Portfolio
16.3.2.4. Business Strategies
16.3.2.5. Recent Developments
16.3.3. Zimmer Biomet
16.3.3.1. Company Overview
16.3.3.2. Financial Overview
16.3.3.3. Product Portfolio
16.3.3.4. Business Strategies
16.3.3.5. Recent Developments
16.3.4. Arthrex, Inc.
16.3.4.1. Company Overview
16.3.4.2. Financial Overview
16.3.4.3. Product Portfolio
16.3.4.4. Business Strategies
16.3.4.5. Recent Developments
16.3.5. Terumo BCT, Inc.
16.3.5.1. Company Overview
16.3.5.2. Financial Overview
16.3.5.3. Product Portfolio
16.3.5.4. Business Strategies
16.3.5.5. Recent Developments
16.3.6. Crown Aesthetics
16.3.6.1. Company Overview
16.3.6.2. Financial Overview
16.3.6.3. Product Portfolio
16.3.6.4. Business Strategies
16.3.6.5. Recent Developments
16.3.7. Celling Biosciences
16.3.7.1. Company Overview
16.3.7.2. Financial Overview
16.3.7.3. Product Portfolio
16.3.7.4. Business Strategies
16.3.7.5. Recent Developments
16.3.8. EmCyte Corporation
16.3.8.1. Company Overview
16.3.8.2. Financial Overview
16.3.8.3. Product Portfolio
16.3.8.4. Business Strategies
16.3.8.5. Recent Developments
16.3.9. Juventix Regenerative Medical, LLC.
16.3.9.1. Company Overview
16.3.9.2. Financial Overview
16.3.9.3. Product Portfolio
16.3.9.4. Business Strategies
16.3.9.5. Recent Developments
16.3.10. APEX Biologix
16.3.10.1. Company Overview
16.3.10.2. Financial Overview
16.3.10.3. Product Portfolio
16.3.10.4. Business Strategies
16.3.10.5. Recent Developments
16.3.11. Dr PRP USA LLC
16.3.11.1. Company Overview
16.3.11.2. Financial Overview
16.3.11.3. Product Portfolio
16.3.11.4. Business Strategies
16.3.11.5. Recent Developments
16.3.12. Changsha Yingtai Instrument Co., Ltd.
16.3.12.1. Company Overview
16.3.12.2. Financial Overview
16.3.12.3. Product Portfolio
16.3.12.4. Business Strategies
16.3.12.5. Recent Developments
16.3.13. Accuquik Test Kits
16.3.13.1. Company Overview
16.3.13.2. Financial Overview
16.3.13.3. Product Portfolio
16.3.13.4. Business Strategies
16.3.13.5. Recent Developments
16.3.14. Aspire Medical Innovation
16.3.14.1. Company Overview
16.3.14.2. Financial Overview
16.3.14.3. Product Portfolio
16.3.14.4. Business Strategies
16.3.14.5. Recent Developments
16.3.15. Factor Medical, Inc.
16.3.15.1. Company Overview
16.3.15.2. Financial Overview
16.3.15.3. Product Portfolio
16.3.15.4. Business Strategies
16.3.15.5. Recent Developments
°ü·ÃÀÚ·á